New filings for Eisai's Fycompa despite reimbursement woes
This article was originally published in Scrip
Eisai has filed its anti-epileptic Fycompa (perampanel) for use as an adjunctive therapy in people with uncontrolled primary generalized tonic-clonic seizures (PGTC), an additional indication, in the US and EU.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.